Blueprint Medicines

Blueprint Medicines is a precision medicine company that specializes in discovering and developing targeted therapies for patients with genomically defined cancers, hematologic disorders, and rare diseases. The company's approach leverages a proprietary drug discovery platform to design highly selective kinase inhibitors that target the root causes of disease. Their flagship product, AYVAKIT (avapritinib), is the first and only FDA-approved therapy for indolent systemic mastocytosis (ISM). In late 2025, Blueprint Medicines was acquired by Sanofi for approximately $9.5 billion, integrating its robust oncology and immunology pipeline into Sanofi's global portfolio. The company continues to operate as a specialized subsidiary, focusing on the expansion of its mast cell disease franchise and the advancement of next-generation inhibitors like elenestinib and BLU-808.